Education
About Us
Working with TipRanks
Follow Us
Neuphoria Therapeutics (NEUP)
NASDAQ:NEUP
Total Valuation
Neuphoria Therapeutics has a market cap or net worth of $22.97M. The enterprise value is -$13.89M.
Market Cap$22.97M
Enterprise Value-$13.89M
Share Statistics
Neuphoria Therapeutics has 5,390,895 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding5,390,895
Owned by Insiders16.28%
Owned by Institutions25.49%
Financial Efficiency
Neuphoria Therapeutics’s return on equity (ROE) is -0.02 and return on invested capital (ROIC) is -2.05%.
Return on Equity (ROE)-0.02
Return on Assets (ROA)-0.01
Return on Invested Capital (ROIC)-2.05%
Return on Capital Employed (ROCE)-0.05
Revenue Per Employee2.99M
Profits Per Employee-46.20M
Employee Count8
Asset Turnover0.55
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Neuphoria Therapeutics is ―. Neuphoria Therapeutics’s PEG ratio is -0.16.
PE Ratio―
PS Ratio0.48
PB Ratio0.40
Price to Fair Value0.40
Price to FCF0.15
Price to Operating Cash Flow0.26
PEG Ratio-0.16
Income Statement
In the last 12 months, Neuphoria Therapeutics had revenue of 23.95M and earned -565.77K in profits. Earnings per share was -0.23.
Revenue23.95M
Gross Profit22.94M
Operating Income-1.73M
Pretax Income-1.28M
Net Income-565.77K
EBITDA-268.02K
Earnings Per Share (EPS)-0.23
Cash Flow
In the last 12 months, operating cash flow was 74.79M and capital expenditures -3.00, giving a free cash flow of 74.79M billion.
Operating Cash Flow74.79M
Free Cash Flow74.79M
Free Cash Flow per Share13.87
Dividends & Yields
Neuphoria Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.70
52-Week Price Change-11.59%
50-Day Moving Average4.06
200-Day Moving Average7.10
Relative Strength Index (RSI)57.48
Average Volume (3m)89.21K
Important Dates
Neuphoria Therapeutics upcoming earnings date is Sep 29, 2025, TBA (Confirmed).
Last Earnings DateFeb 20, 2025
Next Earnings DateSep 29, 2025
Ex-Dividend Date―
Financial Position
Neuphoria Therapeutics as a current ratio of 3.56, with Debt / Equity ratio of 0.17%
Current Ratio3.56
Quick Ratio3.56
Debt to Market Cap<0.01
Net Debt to EBITDA79.71
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Neuphoria Therapeutics has paid -716.90K in taxes.
Income Tax-716.90K
Effective Tax Rate0.56
Enterprise Valuation
Neuphoria Therapeutics EV to EBITDA ratio is 36.72, with an EV/FCF ratio of -0.13.
EV to Sales-0.41
EV to EBITDA36.72
EV to Free Cash Flow-0.13
EV to Operating Cash Flow-0.13
Balance Sheet
Neuphoria Therapeutics has $22.17M in cash and marketable securities with $50.13K in debt, giving a net cash position of $22.12M billion.
Cash & Marketable Securities$22.17M
Total Debt$50.13K
Net Cash$22.12M
Net Cash Per Share$4.10
Tangible Book Value Per Share$5.20
Margins
Gross margin is 94.74%, with operating margin of -7.21%, and net profit margin of -2.36%.
Gross Margin94.74%
Operating Margin-7.21%
Pretax Margin-5.35%
Net Profit Margin-2.36%
EBITDA Margin-1.12%
EBIT Margin-5.35%
Analyst Forecast
The average price target for Neuphoria Therapeutics is $7.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$7.00
Price Target Upside60.92% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast―